Theolytics is a technology company.
Theolytics has raised $7.0M across 1 funding round.
Theolytics has raised $7.0M in total across 1 funding round.
Theolytics is a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies using engineered adenoviruses to target and destroy cancer cells, particularly in hard-to-treat solid tumors.[1][2][4] It serves patients with cancers like platinum-resistant ovarian cancer, colorectal cancer, and hematological malignancies, addressing unmet needs by creating viruses that selectively lyse tumor cells and cancer-associated fibroblasts while activating the immune response and enabling intravenous delivery.[1][3][5][6] The lead program, THEO-260, is in Phase 1/2 clinical trials (OCTOPOD-IV in Europe and OCTOPOD-IP in the US), with preclinical programs advancing, supported by recent £2 million Innovate UK funding and backing from investors like Taiho Ventures, M Ventures, and Oxford Science Enterprises.[1][3][5][6]
Founded in 2017 as a spinout from Oxford University Innovation, Theolytics emerged from research harnessing oncolytic viruses, combining genetic engineering with a library of over 100 million viral variants tested on real patient tumor samples for more translational efficacy.[1][2][6] The leadership team brings over 40 years of experience in oncolytic virus development, with CEO David Apelian (MD PhD MBA) joining recently to advance clinical programs, alongside experts like Dr. Saggese leading trial expansion.[2][5][6] Early traction included securing international funding and initiating first-in-human trials for THEO-260, marking a pivotal shift from preclinical to clinical stage.[1][5]
Theolytics rides the oncolytic virus wave in immuno-oncology, where viruses reprogram tumors to provoke immune attacks, aligning with trends in precision medicine and combination therapies amid rising demand for non-invasive, IV-administrable options.[1][3][5] Timing is ideal post-COVID virotherapy advances and failures of prior generations, with market forces like high ovarian cancer recurrence rates (platinum-resistant cases) and £2M Innovate UK support favoring rapid clinical progress.[1][6] It influences the ecosystem by validating patient-derived screening, potentially accelerating biotech pipelines through partnerships and setting standards for stromal-targeting in solid tumors.[3][6]
Theolytics is poised to advance THEO-260 through Phase 2 readouts, expand preclinical assets into trials, and pursue partnerships for combo regimens in immuno-oncology.[3][5] Trends like AI-driven variant screening and regulatory nods for IV oncolytics will shape growth, potentially evolving its influence from niche ovarian focus to platform leader in tumor microenvironment therapies. This positions Theolytics to deliver transformative outcomes in cancers long underserved by conventional treatments.[1][6]
Theolytics has raised $7.0M in total across 1 funding round.
Theolytics's investors include M Ventures (Merck), Taiho Ventures.
Theolytics has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $7.0M Series A | M Ventures (Merck), Taiho Ventures |